A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
Peter Dubsky(Hirslanden Klinik St. Anna), Martin Filipits(University of Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Ersan Lujinovic(Agendia (Netherlands)), Richard Greil(Paracelsus Medical University), Farid Moinfar(AGO Austria), Daniel Egle(Innsbruck Medical University), Wolfgang Hulla(Fachhochschule Wiener Neustadt), Margaretha Rudas(Comprehensive Cancer Center Vienna), Sophie Frantal(Statistics Austria), Gabriel Rinnerthaler(Medical University of Graz), Walter Herz(LKH Hochsteiermark), LJ van't Veer(University of Minnesota), Jorun Buresch(Medical University of Vienna), Christa Dreezen(Leiden University Medical Center)
Cited by 16
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k